Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of RC48-ADC in HER2-negative advanced or metastatic urothelial carcinoma
CTR20192667Phase 2Active
- Sponsor
- RemeGen
- Start
- Aug 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in transitional cell carcinoma (TCC), sponsored by RemeGen. Started Aug 2019; status: active.
02
Drugs
disitamab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20192667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192667.